Skip to main content
. 2020 Oct 8;34(6):2223–2231. doi: 10.1111/jvim.15927

TABLE 1.

Descriptive data obtained from 2194 dogs with myxomatous mitral valve disease with and without atrial fibrillation (AF)

Variable Category AF group, n = 59 dogs No AF group, n = 2135 dogs P value
Number (%), mean ± SD Missing values, n (%) Number (%), mean ± SD Missing values, n (%)
Breed Crossbred 35 (59.3) 817 (38.3) .002
Purebred 24 (40.7) 1318 (61.7)
Age (mo.) mean ± SD 136 ± 28 136 ± 35 27 (1.3) .69
Sex Female 18 (30.5) 1141 (53.5) 3 (0.1) .001
Male 41 (69.5) 991 (46.5)
BW (kg) Mean ± SD 17.3 ± 10.6 10.7 ± 8.6 11 (0.5) <.001
HR (bpm) Mean ± SD 187 ± 41 1 (1.7) 128 ± 31 5 (0.2) <.001
LA (cm) Mean ± SD 4.98 ± 0.97 1 (1.7) 2.38 ± 0.80 2 (0.1) <.001
Ao (cm) Mean ± SD 1.91 ± 0.48 1 (1.7) 1.60 ± 0.43 2 (0.1) <.001
LA/Ao Mean ± SD 2.72 ± 0.67 1 (1.7) 1.52 ± 0.47 2 (0.1) <.001
LVDDn Mean ± SD 2.06 ± 0.36 1.55 ± 0.32 20 (0.9) <.001
LVSDn Mean ± SD 1.26 ± 0.28 0.85 ± 0.23 22 (1.0) <.001
FS (%) Mean ± SD 36.9 ± 10.4 43.5 ± 9.6 11 (0.5) <.001
E max (m/s) Mean ± SD 1.49 ± 0.37 3 (5.1) 0.83 ± 0.36 19 (0.9) <.001
PH No 31 (52.5) 1638 (76.7) <.001
Yes 28 (47.5) 497 (23.3)
ACVIM stage B1 + B2 6 (10.2) 1861 (87.2) <.001
C + D 53 (89.8) 274 (12.8)
Treatment CT/NT 48 (84.8)/9 (15.8) 263 (14.0)/1619 (86.0) <.001
CT/MT 48 (100.0)/0 (0.0) 263 (84.8)/47 (15.2) .007
CT/OT 48 (96.0)/2 (4.0) 263 (56.1)/206 (43.9) <.001
MT/OT 0 (0.0)/2 (100.0) 47 (18.6)/206 (81.4) .81
MT/NT 0 (0.0)/9 (100.0) 47 (2.8)/1619 (97.2) .62
NT/OT 11 (84.6)/2 (15.4) 206 (11.3)/1619 (88.7) .81

Abbreviations: ACVIM, American College of Veterinary Internal Medicine; AF, atrial fibrillation; BW, body weight; CT, cardiac treatment; E max, mitral valve maximal E wave velocity; FS, fractional shortening; HR, heart rate; LA, left atrial diameter; LA/Ao, left atrial diameter to aortic diameter; LVDDn, left ventricular diastolic diameter normalized to body weight; LVSDn, left ventricular systolic diameter normalized to body weight; MT, mixed treatment; n, number of dogs; NT, no treatment; OT, other treatments; PH, pulmonary hypertension.